News – Page 856 – Endpoints News

Genfit delays high-stakes PhIII NASH readout; Bristol-Myers grabs first Opdivo OK in esophageal cancer

6 years ago

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

6 years ago

Bankrupt antibiotics maker Aradigm turns to old partner/investor for final $3M fire sale

6 years ago

DBV's peanut prevention patch approaches key stage of approval process

6 years ago

Antonio Gualberto starts post-Kura career at Eisai subsidiary H3; eFFECTOR co-founder Siegfried Reich jumps to ...

6 years ago

Say goodbye to Tocagen, struggling brain cancer biotech to reverse merge with Forte Biosciences

6 years ago

Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy

6 years ago

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

6 years ago

Pharmacogenetics: FDA releases table of gene-drug interactions

6 years ago

Heron's Groundhog Day; Vifor forms JV with Fresenius Kabi in China

6 years ago

Fresh off $100M round, GV-backed real-world data startup woos Duke researcher as CMO

6 years ago

Merck loses its chief digital officer, spotlighting talent hunt for the hottest title in Big Pharma

6 years ago

Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout

6 years ago

Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials

6 years ago

Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic

6 years ago

FDA consolidates nonclinical immunotoxicity evaluation guidance

6 years ago

Eli Lilly vet Kerry Blanchard takes the helm at one of China's top dealmakers, steering toward first approvals

6 years ago

TCR-focused Immatics adds another marquee name to its list of partners: GSK

6 years ago

Incyte's topical Jakafi scores again in eczema Phase III; Priority review lines Roche's Tecentriq up for new lung ...

6 years ago

DuPont makes another foray into drug R&D, throwing its name into the microbiome hat

6 years ago

For two decades, a new vaccine technology has been slowly approaching prime time. Now, can it stop a pandemic?

6 years ago

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

6 years ago

Bristol-Myers shrugs off another Opdivo combo flop as $1.74B deal goes pfffft

6 years ago

Biotech CEO who lied about curing his own paralysis sentenced to 7 years in jail

6 years ago

First page Previous page 853 854 855856857 858 859 Next page Last page